Margaret Winkler, MD
Internal Medicine · Hammond, LANPI 1457362147
Payments from drug & device makers
Across 248 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$501
- GSK$467
- AstraZeneca$425
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$328
- Pfizer$309
- Novartis$233
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,96599%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $501 |
| GSK | 26 | $467 |
| AstraZeneca(2 entities) | 24 | $425 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $328 |
| Pfizer | 20 | $309 |
| Novartis | 13 | $233 |
| Amgen | 12 | $198 |
| Novo Nordisk | 10 | $163 |
| Scilex Pharmaceuticals Inc. | 8 | $155 |
| Esperion Therapeutics, Inc. | 9 | $149 |
| Lilly USA, LLC | 6 | $82 |
| Merck | 6 | $81 |
| Johnson & Johnson | 4 | $78 |
| Astellas Pharma US Inc | 5 | $77 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| Mannkind Corporation | 1 | $59 |
| Almatica Pharma LLC | 3 | $58 |
| Sunovion Pharmaceuticals Inc. | 10 | $57 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Kowa Pharmaceuticals America, Inc. | 3 | $50 |
| Renalytix AI, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Lundbeck LLC | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Gilead | 1 | $24 |
| Ardelyx, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Exact Sciences | 1 | $22 |
| Alkermes, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 5 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
How this compares
$4,024 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 145 | $153,149 |
| EliquisApixaban | 146 | $92,235 |
| OzempicSemaglutide | 84 | $87,657 |
| Humira PenAdalimumab | 12 | $81,740 |
| JanuviaSitagliptin Phosphate | 67 | $37,798 |
| LinzessLinaclotide | 62 | $36,265 |
| JardianceEmpagliflozin | 49 | $32,814 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $23,004 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $21,866 |
| FarxigaDapagliflozin Propanediol | 24 | $17,019 |
| TrulicityDulaglutide | 18 | $16,688 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $15,589 |
| GemtesaVibegron | 27 | $14,832 |
| MyrbetriqMirabegron | 25 | $11,336 |
| NamzaricMemantine Hcl/Donepezil Hcl | 13 | $9,112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $82 | $169,836163 claims |
| PfizerEliquis | $309 | $92,235146 claims |
| Novo NordiskOzempic | $163 | $87,65784 claims |
| AbbVieLinzess, Namzaric | $501 | $45,37775 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $467 | $45,00088 claims |
| MerckJanuvia | $81 | $37,79867 claims |
| Boehringer IngelheimJardiance | $17 | $32,81449 claims |
| AstraZenecaFarxiga, Symbicort | $425 | $20,28539 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $14,83227 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $11,33625 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $39 | $7,45916 claims |
| Johnson & JohnsonXarelto | $78 | $6,53812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Hammond
- Anthony ZerangueHammond$20K
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.